AstraZeneca PLC Block listing Interim Review (4365V)

TIDMAZN

RNS Number : 4365V

AstraZeneca PLC

01 December 2023

1 December 2023 15:05 GMT

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

Date : 1 December 2023

 
 Name of applicant:                                  ASTRAZENECA PLC 
 Name of scheme:                                     ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE 
                                                     OPTION PLAN; ASTRAZENECA 
                                                     ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED 
                                                     SHARE OPTION SCHEME 
                                                    ------------------------------------------------------------------ 
 Period of return:          From:                    1 JUNE 2023                To:            30 NOVEMBER 2023 
                           -----------------------  -------------------------  -------------  ------------------------ 
 Balance of unallotted securities under scheme(s) 
  from previous return:                              4,476,382 
                                                    ------------------------------------------------------------------ 
 Plus: The amount by which the block scheme(s) has 
  been increased since the date of the last 
  return (if any increase has been applied for):     0 
                                                    ------------------------------------------------------------------ 
 Less: Number of securities issued/allotted under 
  scheme(s) during period (see LR3.5.7G):            56,248 
                                                    ------------------------------------------------------------------ 
 Equals: Balance under scheme(s) not yet 
  issued/allotted at end of period:                  4,420,134 
                                                    ------------------------------------------------------------------ 
 
 
 
 Name of contact:                Hannah Tattersall 
 Telephone number of contact:    [phone] 
                                -------------------- 
 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca .

Contacts

For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRFSSFEFEDSELE

(END) Dow Jones Newswires

December 01, 2023 10:05 ET (15:05 GMT)